MarkNtel Advisors, a leading market research and consulting firm, has announced the release of its latest study titled Transthyretin Amyloidosis Treatment Market Research Report: Forecast (2026–2032). This report provides a detailed assessment of the Transthyretin Amyloidosis Treatment Market, covering its evolving dynamics, emerging trends, key growth drivers, major challenges, and competitive landscape.

Designed to guide investors, stakeholders, and business leaders, the research aims to deliver valuable insights for strategic planning, risk assessment, and investment decision-making in the years ahead.

Market Timeline Overview

• Historical Years: 2021–24
• Base Year: 2025
• Forecast Years: 2026–32

This helps businesses identify emerging opportunities, assess market risks, and develop data-driven strategies for long-term success.

Download a FREE PDF Sample of the Report: https://www.marknteladvisors.com/query/request-sample/transthyretin-amyloidosis-treatment-market.html (Discover the market potential, platform-specific insights, and key industry trends.)

Transthyretin Amyloidosis Treatment Market Outlook

According to the report The Global Transthyretin Amyloidosis Treatment Market size is valued at around USD5.88 billion in 2025 and is projected to reach USD13.58 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 12.70% during the forecast period, i.e., 2026-32.

The report also examines consumer preferences, regulatory impacts, and investment trends that will shape the market’s trajectory over the next decade.

Transthyretin Amyloidosis Treatment Market Drivers:

Increasing Investments for Rare-Disease Research and Clinical Infrastructure- Growing investment in rare-disease research and clinical infrastructure is accelerating progress in transthyretin amyloidosis (ATTR) treatment worldwide. The U.S. National Institutes of Health (NIH) remains the largest public funder of rare-disease research, investing about USD26 million for rare disease conditions, including amyloidosis.

View Full Report (All Data, In One Place): https://www.marknteladvisors.com/research-library/transthyretin-amyloidosis-treatment-market.html (Explore in-depth analyses, technological trends, and investment patterns.)

Transthyretin Amyloidosis Treatment Market Trends:

Shift Toward Next-Generation RNA & Digital Diagnostic Tools- A major trend shaping the ATTR treatment landscape is the rapid shift toward next-generation RNA-based medicines. Companies such as Alnylam and Ionis are developing newer RNA therapies designed for longer durability and easier dosing. For instance, in March 2025, the FDA expanded approval for vutrisiran (Amvuttra) to treat ATTR cardiomyopathy, widening RNA-interference options for patients in the United States. This regulatory milestone reflects growing physician confidence in RNA-based therapies because of their proven ability to reduce transthyretin production and slow disease progression.

Transthyretin Amyloidosis Treatment Market Segmentation

The study categorizes the Transthyretin Amyloidosis Treatment Market into various segments and sub-segments, each analyzed for its size, growth potential, and contribution to the overall industry.

By Type- (USD Million)

• ATTR amyloidosis with polyneuropathy
• ATTR amyloidosis with cardiomyopathy

By Disease Type- (USD Million)

• Hereditary Transthyretin Amyloidosis
  • Polyneuropathy
  • Cardiomyopathy
  • Mixed type
• Wild-type transthyretin amyloidosis

By Drug Type- (USD Million)

• Tafamidis
• Patisiran
• Inotersen
• Other drug types

By Route of Administration

• Oral
• Parental

By Distribution Channel

• Hospital pharmacy
• Retail drug stores
• Online pharmacy

Geographical Analysis

The report presents detailed insights into the market’s geographical expansion, highlighting key trends and opportunities across the following geographies:

By Region

• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

Talk to Our Industry Analyst: https://www.marknteladvisors.com/query/talk-to-our-consultant/transthyretin-amyloidosis-treatment-market.html Get personalized insights into company strategies and regional market dynamics.)

Leading Companies in Transthyretin Amyloidosis Treatment Market Worldwide: Players, Analysis & Future Outlook

• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals Inc.
• AstraZeneca Plc
• Astellas Pharma Inc
• Bridge-Myers Squibb Company
• Ionis Pharmaceuticals, Inc
• Johnson and Johnson
• Prothena Bioscience Limited
• Pfizer Inc.
• SOM Innovation Biotech, SL
• Others

Key Highlights of the Report

• Comprehensive Market Overview: In-depth analysis of market size, share, and forecasts from 2026 to 2032.
• Growth Drivers & Challenges: Clear insights into factors feeling or restraining market expansion.
• Investment & Regulatory Insights: Evaluation of key policies, funding trends, and collaborations influencing industry performance.
• Competitive Landscape: Detailed profiles of leading companies, including product portfolios, business strategies, financials, and recent developments such as mergers & acquisitions.

Analytical Tools: Application of SWOT Analysis, PESTEL Analysis, and Porter’s Five Forces Model to assess competition and external influences

Browse through our flexible pricing plans and choose the package that best fits your business needs whether you require a single-user license, corporate access, or customized insights. Once you select the plan that suits your requirements, you can purchase and instantly access the full report online –  https://www.marknteladvisors.com/pricing/transthyretin-amyloidosis-treatment-market.html

Frequently Asked Questions (FAQ)

1. What is the projected growth rate of the Transthyretin Amyloidosis Treatment Market?
   2. What are the major factors driving this market’s growth?
   3. Which regions are expected to lead the Transthyretin Amyloidosis Treatment Market?
   4. Who are the prominent players in the Transthyretin Amyloidosis Treatment Market?
   5. How is the competition structured in this market?
   6. How can I access the full report?

About Us

MarkNtel Advisors is a globally recognized market research and consulting firm delivering intelligence across the healthcare industry, spanning pharmaceuticals, medical devices, healthcare IT, and biotechnology. Our analysts combine domain expertise with innovation tracking to help healthcare organizations improve efficiency and patient outcomes. Through Consulting Services, we assist clients in interpreting insights, designing go-to-market strategies, and adapting to regulatory changes, fostering sustainable growth in the evolving global healthcare ecosystem.

Contact Us:
MarkNtel Advisors
Sector 63, Noida, Uttar Pradesh-201301, India
Contact No: +91 87199 99009
Email: sales@marknteladvisors.com
Website: https://www.marknteladvisors.com